Biomedical Engineering Reference
In-Depth Information
Chow, S. and Liu, J. 2004.
Design and Analysis of Clinical Trials
. Wiley.
Crommelin, D. 2002.
Pharmaceutical Biotechnology
. Routledge.
De Jong, M. 1998.
FAQs on EU Pharmaceutical Regulatory Affairs
. Brookwood Medical Publications.
Desalli, R. 2002.
The Genomics Revolution
. Joseph Henry Press.
Everitt, B. and George, S. 2004.
Textbook of Clinical Trials
. Wiley.
Ferraiolo, B. 1992.
Protein Pharmacokinetics and Metabolism
. Plenum Publishers.
Goldberg, R. 2001.
Pharmaceutical Medicine, Biotechnology and European Patent Law
. Cambridge University
Press.
Grindley, J. and Ogden, J. 2000.
Understanding Biopharmaceuticals. Manufacturing and regulatory Issues
.
Interpharm Press.
Knight, H. 2001.
Patent Strategy
. Wiley.
Krogsgaard, L. 2002.
Textbook of Drug Design and Discovery
. Taylor and Francis.
McNally, E. (ed.). 2000.
Protein Formulation and Delivery
. Marcel Dekker.
Oxender, D. and Post, L. 1999.
Novel Therapeutics from Modern Biotechnology
. Springer Verlag.
Pennington, S. 2000.
Proteomics
. BIOS Scientifi c Publishers.
Pisano, D. and Mantus, D. 2003. FDA
Regulatory Affairs, a Guide for prescription Drugs, Medical Devices and
Biologics
. CRC Press.
Poste, G. 1999.
The Impact of Genomics on Healthcare
. Royal Society of Medicine Press.
Rehm, H. 2005.
Protein Biochemistry and Proteomics
. Academic Press.
Scolnick, E. 2001.
Drug Discovery and Design
. Academic Press.
Venter, J. 2000.
From Genome to Therapy
. Wiley.
Articles and websites
Clinical trials, development and regulatory
Chirino, A.J., Ary, M.L., and Marshall, S.A. 2004. Minimizing the immunogenicity of protein therapeutics.
Drug Discovery Today
9
, 82-90.
European Medicines Agency Website: http://www.emea.eu.int.
FDA Website: http://www.fda.gov.
Graffeo, A. 1994. The do's and don'ts of preclinical development.
Bio/Technology
12
, 865.
Helms, P. 2002. Real world pragmatic clinical trials: what are they and what do they tell us?
Pediatric Allergy
and Immunology
13
(1), 4 -9.
Hermeling, S., Crommelin, D.J.A., Schellekens, H., and Jiskoot, W. 2004. Structure-immunogenicity relation-
ships of therapeutic proteins. Pharmaceutical research,
21
, 897-903.
Jefferys, D. and Jones, K. 1995. EMEA and the new pharmaceutical procedures for Europe.
European Journal
of Clinical Pharmacology
47
, 471-476.
Lubiniecki, A. 1997. Potential infl uence of international harmonization of pharmaceutical regulations on biop-
harmaceutical development.
Current Opinion in Biotechnology
8
(3), 350-356.
Mahmood, I. and Green, M. 2005. Pharmacokinetic and pharmacodynamic considerations in the development of
therapeutic proteins.
Clinical Pharmacokinetics
44
(4), 331-347.
Pignatti, F., Aronsson, B., Vamvakas, S., Wade, G., Papadouli, I., Papaluca, M., Moulon, I., and Courtois, P.L.
2002. Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology.
Critical
Reviews in Oncology Haematology
42
(2), 123-135.
Schwardt, O., Kolb, H., and Ernst, B. 2003. Drug discovery today.
Current Topics in Medicinal Chemistry
3
(1),
1-9.
Shankar, G., Shores, E., Wagner, C., and Mire-Sluis, A. 2006. Scientifi c and regulatory considerations on the
immunogenicity of biologics.
Trends in Biotechnology
24
, 274-280.
Search WWH ::
Custom Search